Navigation Links
Survey of American women finds STD vaccine viewed positively
Date:8/24/2010

INDIANAPOLIS -- Cost but not convenience plays a significant role in attitudes about vaccination for common human papillomaviruses for women over the age of 26, according to the authors of a recent article in the journal Sexual Health.

Currently, the two vaccines for human papillomavirus (HPV), which is the primary cause of cervical cancer, are U.S. Food and Drug Administration approved for females from 9 to 26 years of age. The vaccines, Gardasil (Merck and Co.) and Cervarix (GlaxoSmithKline) are under review by the FDA for an older population of women.

Researchers from Indiana University School of Medicine and Columbia University Medical Center surveyed 1,323 women between 27 and 55 years of age who represent a racial and demographic cross section of the United States to determine the willingness among adult women to be vaccinated.

"We have been involved for several years in research looking at the attitudes toward HPV vaccination and acceptance of vaccine," said senior author and co-principal investigator Gregory D. Zimet, Ph.D., professor of pediatrics and clinical psychology in the Section of Adolescent Medicine at the IU School of Medicine. "This project looked at an older population of women to determine their attitudes about HPV vaccination and what factors influenced their attitudes."

Researchers found moderately strong interest in receiving the vaccination if it is available free of charge, said first author Nathan W. Stupiansky, Ph.D., a fellow with the IU Department of Pediatrics, Section of Adolescent Medicine. As out-of-pocket costs increased, interest decreased for the vaccine, which typically costs $120 per dose and requires three doses.

The survey also queried women as to whether they would prefer receiving the vaccine at a doctor's office or a local pharmacy to gauge if convenience played a factor in acceptance. The preferred choice by a slight edge was a doctor's office.

Factors that did not increase interest in the vaccine included having a friend or relative who had cervical cancer or personally having had a prior sexually transmitted infection.

Increased acceptibility was found in women who had experienced a genital warts outbreak, had at least one abnormal Pap test, previously had heard about the HPV vaccine or who had had a flu shot within the past two years.

"With the accumulating empirical evidence that vaccination of women over the age of 26 can be beneficial, it is important to understand specific factors associated with HPV vaccine acceptability," said Dr. Stupiansky. "This study clarifies some of the issues for acceptance including cost and prior knowledge of the vaccine.

The findings of the research also suggest that interest in the vaccine among adult women may be substantially dampened if insurance coverage does not reduce the out-of-pocket costs of HPV vaccination. Health insurance and/or public financing (the Vaccine for Children Program) covers HPV vaccination costs for virtually all females 9 through 17 years of age.

HPV is the most common sexually transmitted infection in the U.S. and can be found in more than 25 percent of all women aged 14 to 59 years. The highest rates are among women between the ages of 20 and 24 years but remain above 25 percent for women up to age 49. An estimated 1.6 million new infections occur each year in women older than 26 years of age. HPV is responsible for all cases of cervical cancer and genital warts and is the cause of some cases of anal, throat, vulvar and vaginal cancers.


'/>"/>

Contact: Mary L. Hardin
mhardin@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert

Related medicine news :

1. New state surveys affirm Americans support for government action on climate change
2. Survey of coastal residents shows Gulf oil spill has significant impact on families
3. Global HIV/AIDS survey by IAPAC reveals critical gap in patient-physician conversations
4. MD Anderson keeps No. 1 cancer ranking in US News & World Report annual survey
5. 1 in 5 Parents Missed Work for H1N1 School Closings: Survey
6. Survey Links Puberty to Violent Behavior
7. PBG Offers a Pre-Upgrade Site Survey for Ericom, VMware, and NetApp Upgrades
8. Green And Greener Survey Shows Hospitals Embrace Environmentally Sustainable Practices, Though Room for Improvement Remains
9. More Than Half of Pediatricians Make Diagnostic Errors: Survey
10. European patient survey add weight to expert call for greater clinical consensus on BTCP
11. Survey highlights major Canada-US differences in people in middle age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... ... leading digital and print media enterprise focused on cancer patients, cancer centers and ... released a special 12-part educational video series, “No Ifs, Ands, or Butts,” that ...
(Date:3/22/2017)... ... 22, 2017 , ... The Rett Syndrome Research Trust (RSRT) ... that afflicts 350,000 individuals worldwide. Rett Syndrome is caused by alterations in ... females. Following a normal infancy, Rett Syndrome takes effect in toddlerhood depriving ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... to its Department of Orthopedic Surgery, Division of Hand, Upper Extremity and Microvascular ... surgery. She is board-certified in both Orthopedics and Hand Surgery. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic Imaging, ... therapeutic experience and operational excellence in oncology clinical trials, proudly announces today that ... treatment of non-small cell lung cancer and small cell lung cancer. , Throughout ...
(Date:3/22/2017)... Norwich, NY (PRWEB) , ... March 22, 2017 , ... ... to communities in the greater Nassau County region, is embarking on a combined charity ... breast cancer. , For the last 25 years, the Great Neck Breast Cancer ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... March 22, 2017 AMRI , a ... been working with the life sciences industry to improve ... 25 years, has been recognized for its excellence as ... as part of the Life Science Leader,s 2017 ... expertise, quality and reliability. "Competing with ...
(Date:3/22/2017)... STOCKHOLM , March 22, 2017 ... biopharmaceutical company developing novel anticancer therapies targeting the ... with Memorial Sloan Kettering Cancer Center to study ... p53 by APR-246. The goal of ... efficacy of APR-246 in combination with multiple other ...
(Date:3/22/2017)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 14.58% during the period ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology: